Vasiliki Sgouropoulou1,2, Evangelia Farmaki3, Theophanis Papadopoulos4, Vasiliki Tzimouli3, Jenny Pratsidou-Gertsi3, Maria Trachana3. 1. 1st Department of Paediatrics, Paediatric Immunology and Rheumatology Referral Center, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. vsgouro@hotmail.com. 2. , Konstantinoupoleos 49, Thessaloniki, 54642, Greece. vsgouro@hotmail.com. 3. 1st Department of Paediatrics, Paediatric Immunology and Rheumatology Referral Center, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. 4. Karyo Centre, Laboratory of Molecular Biology and Genetics, Karyo Center, Thessaloniki, Greece.
Abstract
INTRODUCTION/ OBJECTIVES: Familial Mediterranean Fever (FMF) is a genetic disorder of the innate immunity characterized by chronic inflammatory state. The diagnosis is mainly based on clinical criteria and supported by genotyping, especially in atypical phenotypes. The primary objective was to depict the Familial Mediterranean Fever (FMF) genotype of Greek patients and investigate the contribution of Next Generation Sequencing (NGS) beyond the contemporary techniques [(Polymerase Chain Reaction (PCR)/hybridization and Non-Isotopic RNase Cleavage Assay (NIRCA). The secondary objective was to unravel any associations between the mutated genes with the disease course and response to treatment. METHODS: In this single center, retrospective study 31 patients with clinical diagnosis with FMF, but non-conclusive genetic analysis with PCR/hybridization and NIRCA, underwent NGS genotyping. RESULTS: PCR/NIRCA detected ≥ 1 mutation in 25/31 patients, most frequently M694V (29%), while NGS in 26/31 (83.9%), most frequently R202Q (61.3%). NGS genetically confirmed the clinical diagnosis (heterozygosity to compound or complex genotype) in 19 (61.3%) patients of our cohort. R202Q was significantly more prevalent by NGS than by contemporary techniques (61.3 vs 12.9%, p = 0.0002) and was associated with FMF. Rare mutations were detected by NGS in 19.2% patients. CONCLUSION: NGS clarifies the genetic profile of patients with atypical phenotypes and supports therapeutic management decisions. NGS unveiled the frequent involvement of R202Q in the pathogenesis of our FMF patients.
INTRODUCTION/ OBJECTIVES: Familial Mediterranean Fever (FMF) is a genetic disorder of the innate immunity characterized by chronic inflammatory state. The diagnosis is mainly based on clinical criteria and supported by genotyping, especially in atypical phenotypes. The primary objective was to depict the Familial Mediterranean Fever (FMF) genotype of Greek patients and investigate the contribution of Next Generation Sequencing (NGS) beyond the contemporary techniques [(Polymerase Chain Reaction (PCR)/hybridization and Non-Isotopic RNase Cleavage Assay (NIRCA). The secondary objective was to unravel any associations between the mutated genes with the disease course and response to treatment. METHODS: In this single center, retrospective study 31 patients with clinical diagnosis with FMF, but non-conclusive genetic analysis with PCR/hybridization and NIRCA, underwent NGS genotyping. RESULTS: PCR/NIRCA detected ≥ 1 mutation in 25/31 patients, most frequently M694V (29%), while NGS in 26/31 (83.9%), most frequently R202Q (61.3%). NGS genetically confirmed the clinical diagnosis (heterozygosity to compound or complex genotype) in 19 (61.3%) patients of our cohort. R202Q was significantly more prevalent by NGS than by contemporary techniques (61.3 vs 12.9%, p = 0.0002) and was associated with FMF. Rare mutations were detected by NGS in 19.2% patients. CONCLUSION: NGS clarifies the genetic profile of patients with atypical phenotypes and supports therapeutic management decisions. NGS unveiled the frequent involvement of R202Q in the pathogenesis of our FMF patients.
Authors: Daniel C Koboldt; Karyn Meltz Steinberg; David E Larson; Richard K Wilson; Elaine R Mardis Journal: Cell Date: 2013-09-26 Impact factor: 41.582
Authors: A Bernot; C da Silva; J L Petit; C Cruaud; C Caloustian; V Castet; M Ahmed-Arab; C Dross; M Dupont; D Cattan; N Smaoui; C Dodé; C Pêcheux; B Nédelec; J Medaxian; M Rozenbaum; I Rosner; M Delpech; G Grateau; J Demaille; J Weissenbach; I Touitou Journal: Hum Mol Genet Date: 1998-08 Impact factor: 6.150
Authors: Marta Rusmini; Silvia Federici; Francesco Caroli; Alice Grossi; Maurizia Baldi; Laura Obici; Antonella Insalaco; Alberto Tommasini; Roberta Caorsi; Eleonora Gallo; Alma Nunzia Olivieri; AngeloValerio Marzano; Domenico Coviello; Roberto Ravazzolo; Alberto Martini; Marco Gattorno; Isabella Ceccherini Journal: Ann Rheum Dis Date: 2015-09-17 Impact factor: 19.103
Authors: Sadakatsu Ikeda; Sheryl K Elkin; Brett N Tomson; Jennifer L Carter; Razelle Kurzrock Journal: Cancer Biol Ther Date: 2018-10-19 Impact factor: 4.742